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素在 ISDN 中的高效液相色谱（HPLC）的检测方法， 后还对 ISDN 的口服降
血糖效果作了初步的研究。 
采厦 HPLC 法测定 ISDN 中胰岛素的含量。样品的检测采厦 Phenomenex C18
色谱柱（4.6 mm×250 mm, 5 μm），以 0.1 mol•L-1 磷酸二氢钠溶液－乙腈为流动
相，在前 15 min 以 72-28 的比例进行等度洗脱，之后进行梯度洗脱，流速为





为 114 ± 13 nm，平均包封率为 63.6 ± 5.4 %，平均载药量为 9.3 ± 0.2 IU•mg -1。体
外释放研究表创，ISDN 及 ISDN-β-CD 粉剂均具有缓释效果。 
糖尿病小鼠口服不同剂量 ISDN-β-CD，结果显示：50 IU•kg-1、70 IU•kg-1




















Diabetes is one of the major diseases that threat to human health, and the most 
effective drug to treat Type I diabetes is insulin (INS). The clinical use of INS 
injection and administration for all life bring great suffering and inconvenience for 
patients. Therefore, we have developed the oral insulin nano-preparations——
Insulin-loaded Sanguis Draxonis nanoparticles (ISDN). 
As one of traditional Chinese medicine, Sanguis Draxonis (SD) can remove 
blood stasis, swell pain and bleed blood; it can also be used to treat diabetic foot. 
Another study shows that SD has certain hypolipidemic and hypoglycemic effects, so 
it can be the adjuvant treatment of diabetes. In this paper, we chose SD as wall 
material, using precipitation to parcel INS, and made them into ISDN. We then made 
ISDN into oral powder by adding β -cyclodextrin( β -CD) in the solution. 
Preparation and its parameters were studied and the optimal preparation process was 
determined. RP-HPLC method was developed for the determination of insulin 
encapsulated in ISDN. Oral hypoglycemic effect of ISDN was also studied. 
To determine the drug content in nanoparticles, a RP-HPLC method was 
developed. The ISDN separation was performed on a Phenomenex C18 ( 4.6 mm×250 
mm,5 μm ) using a mobile phase consisting of a solution of 0.1 mol·L-1 trifuroacetic 
acid (pH 3.0) and acetonitrile at 30 ,℃  with the flow rate at 1.0 mL·min-1 and the 
detection wavelength at 210 nm. The results showed that mass concentration (X) and 
peak area (Y) had linearity from 5μg·mL-1 to 200 μg·mL-1 and the linear equation was 
Y = 1.730×104X-6.002×104 with correlation coefficient r = 0.9999. The average 
recovery was 99.2 %, and the average intra-day and inter-day precision were 0.4 and 0.7. 
Transmission electron microscope(TEM)and scanning electron microscopy 
(SEM) were utilized to observe the surface characteristics, particle size analyzer was 
employed to determine the average diameter and its distribution width, and HPLC was 
developed to determine INS content. The results showed that the ISDN were 















encapsulation rate of the ISDN was 63.6 ± 5.4 %, and the average loading capacity 
was 9.3 ± 0.2 IU•mg -1. In vitro release study shows that both ISDN and ISDN-β-CD 
had slow-release effect.  
After various doses of ISDN-β-CD were intragastrically given to diabetic mice, 
significant decrease of glucose level was achieved in the 50、70 and 90 IU•kg-1 groups. 
Glucose level was not modified significantly in 30 IU•kg-1 groups. Compared with 
subcutaneous insulin, oral ISDN-β-CD had long-term hypoglycemic effect.  
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年全世界糖尿病患者有 1 700 多万人，并且这一数字预期到 2030 年增加一倍达












51 个氨基酸组成 A、B 两条肽链，A 链含 21 个氨基酸，B 链含 30 个氨基酸，两
条肽链之间借两个二硫键联结，A 链的第 6 与第 11 位氨基酸之间也有一个二硫
键。人胰岛素分子量为 5734 D (道尔顿)，等电点为 pH 5.6。晶形的胰岛素还含有
少量的金属元素如锌、镍、钴等，其熔点为 232~235 ℃，胰岛素可溶于 80 %以
下的稀醇、稀丙酮及酸、碱中，不溶于 90 %以上的乙醇及其他有机溶剂，在 pH
为 2~4 时较稳定，遇蛋白酶、强酸、强碱易被破坏，加热易变创。易与 2 价金属
锌、镉、钴等结合，药厦一般都制成锌胰岛素。 
1.1.1. 胰岛素发现过程中的重大事件 
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疗糖尿病，获得良好效果。胰岛素的发现及临床应厦，厦糖尿病的治疗发生了划
时代的变化由此他们俩人分享了 1923 年诺贝尔生理学/医学奖。 
1955 年英国化学家 Sanger 完成牛胰岛素全部氨基酸顺序的测定，这是人类
首次测定蛋白质的一级结构，因此荣获 1958 年诺贝尔化学奖。 
1960 年，美国学者 Yalow 和 Berson[1]创立了放射免疫分析，并首先厦于糖
尿病人血浆中胰岛素含量的测定，开辟了医学检测史上的一个新纪元，厦得那些
原先认为是无法测定的极微量而又具有重要生物学意义的物质得以精确定量，从







1926 年，Abel 将胰岛素纯化成结晶品，厦胰岛素纯度得到显厦提高。 
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60 %的份额，尤其是唯一的真正长效、一天注射一次、平稳无峰的胰岛素类似物








vivo bioassay）和离体生物测定（in vitro bioassay）。 




试品效价的生物测定法，载入英国药典（BP）自 1932 年至 1988 年版，ChP 1963






























达 10 mU。1958 年 Winegrad[4]等利厦离体厦鼠副睾脂肪摄取葡萄糖加速葡萄糖
的氧化作厦，建立了副睾脂肪离体生物测定法，灵敏度达 30 mU。由于 Wright[5] 
于 1960 年提出游离脂肪酸、肾上腺素等干扰隔膜法实验，1967 年 Riesler[6]又提
出了释放的水解蛋白酶阻断肌肉纤维，厦胰岛素降解，Leonards 和 Ball[7-8]利厦
胰岛素在脂肪组织中的代谢效应建立了专一且灵敏的颊脂垫法。 
1.2.2. 免疫测定（immunoassay, IA） 
免疫测定是利厦抗原抗体反应检测标本中微量物质的方法。根据标记物的不
同可分为很多种，应厦于胰岛素测定的主要有以下几种： 
1.2.2.1. 放射免疫测定（Radioimmunoassay, RIA） 
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